Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 07:00 ET | Source: Evoke Pharma, Inc.

Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety...
May 18, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Patient Experience Survey Reported Positive Findings for GIMOTI®

SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and...
May 17, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Present at H.C. Wainwright Global Investment Conference

SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
May 10, 2022 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2022 Financial Results

SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...
May 03, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
April 26, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
April 19, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List

SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
March 10, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape

SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
March 08, 2022 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare...
March 01, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...